Lundbeck refinances €700M multicurrency revolving credit facility
What's the deal? Danish pharmaceutical company LundbeckDealroom has a profile for this one. Try Dealroom → has refinanced its €700M multicurrency revolving credit facility, replacing its existing arrangement with a new syndicated deal. The transaction was completed with a group of Nordic and international lenders, including Danske BankDealroom has a profile for this one. Try Dealroom →, Bank of AmericaDealroom has a profile for this one. Try Dealroom →, BNP ParibasDealroom has a profile for this one. Try Dealroom →, NordeaDealroom has a profile for this one. Try Dealroom →, SEBDealroom has a profile for this one. Try Dealroom →, and Jyske BankDealroom has a profile for this one. Try Dealroom →. Law firm PlesnerDealroom has a profile for this one. Try Dealroom → advised Lundbeck on the deal.
Why now? The refinancing is designed to strengthen Lundbeck's financing platform, supporting its ongoing business activities and future strategic direction. Replacing an existing facility before it matures is standard practice for large corporates looking to lock in favourable terms and maintain financial flexibility.
The signal: Lundbeck's ability to assemble a six-bank syndicate spanning Nordic corporates like Danske Bank, Nordea, and SEB alongside global heavyweights such as Bank of America and BNP Paribas underscores strong lender confidence in the mature pharma company's brain-disease-focused pipeline. For a company at Lundbeck's growth stage, locking in a €700M facility of this breadth provides significant optionality — whether for bolt-on acquisitions, pipeline expansion, or navigating an uncertain macro environment.
Read more: Plesner
Image: Lundbeck entrance building, Toxophilus / Wikimedia Commons, CC BY-SA 4.0.
